Hints and tips:
...The company had already outlined $500mn cost cuts and announced in November the departure of Al Sandrock, the company’s former head of research, who had led development work on Aduhelm....
...the neuroscience business should not “shock investors but is likely to raise a debate over possible use of proceeds should any cash be generated and management of any earnings dilution [ie deleveraging v...
...Funds may have sold out of Valeant, Apple et al before the rot set in....
...— Recent research by Gorton et . al about the form and role of banks as maturity transformers and creators of “private money” is very relevant to this discussion....
...(Financial Times) Valeant Pharmaceuticals is preparing to take its bid for Allergan direct to shareholders after its latest $53bn offer was rejected by the maker of Botox....
...Why would the Chinese, Russians, Brazilians et al make the same mistake when it is very clearly in the public domain?...
...Pharmaceuticals of Belgium....
...Merck, the German pharmaceuticals and chemicals company, has agreed to buy Millipore, the US laboratory supplies maker, for $7.2bn, including net debt....
...Sanofi-Aventis, one of the world’s largest drugmakers, has approached big shareholders of Belgium’s Solvay about buying its pharmaceuticals division, thought to be worth €5bn ($6.6bn)....
...Entertainment was provided by British comedian Al Murray and a colourful troupe of can-can dancers....
International Edition